Diversified Trust Co. Boosts Holdings in Pfizer Inc. $PFE

Diversified Trust Co. increased its position in Pfizer Inc. (NYSE:PFE) by 15.1% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 153,067 shares of the biopharmaceutical company’s stock after purchasing an additional 20,136 shares during the period. Diversified Trust Co.’s holdings in Pfizer were worth $3,811,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of the company. Grey Fox Wealth Advisors LLC purchased a new position in Pfizer in the third quarter worth about $29,000. Howard Hughes Medical Institute bought a new stake in shares of Pfizer during the second quarter valued at approximately $30,000. Darwin Wealth Management LLC purchased a new position in Pfizer in the 2nd quarter worth approximately $32,000. True Wealth Design LLC raised its holdings in Pfizer by 302.5% in the 3rd quarter. True Wealth Design LLC now owns 1,296 shares of the biopharmaceutical company’s stock worth $33,000 after acquiring an additional 974 shares during the last quarter. Finally, Sagard Holdings Management Inc. bought a new position in Pfizer in the 2nd quarter valued at approximately $36,000. 68.36% of the stock is currently owned by institutional investors.

Pfizer Stock Performance

Shares of PFE opened at $26.98 on Wednesday. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.16 and a quick ratio of 0.87. Pfizer Inc. has a one year low of $20.92 and a one year high of $27.94. The firm has a market capitalization of $153.39 billion, a P/E ratio of 19.83 and a beta of 0.47. The business has a fifty day moving average of $26.75 and a 200 day moving average of $25.64.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 earnings per share for the quarter, beating analysts’ consensus estimates of $0.57 by $0.09. The company had revenue of $17.56 billion for the quarter, compared to the consensus estimate of $16.93 billion. Pfizer had a return on equity of 20.48% and a net margin of 12.42%.Pfizer’s revenue was down 1.2% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.63 earnings per share. As a group, sell-side analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current year.

Wall Street Analyst Weigh In

PFE has been the subject of a number of research analyst reports. Royal Bank Of Canada initiated coverage on Pfizer in a report on Tuesday, February 24th. They issued an “underperform” rating and a $25.00 target price for the company. Cantor Fitzgerald reaffirmed a “neutral” rating and set a $27.00 price objective on shares of Pfizer in a research report on Wednesday, February 4th. Wolfe Research set a $24.00 price objective on Pfizer and gave the stock an “underperform” rating in a report on Wednesday, December 17th. Morgan Stanley set a $27.00 target price on Pfizer and gave the stock a “positive” rating in a research report on Tuesday, March 17th. Finally, Zacks Research raised shares of Pfizer from a “strong sell” rating to a “hold” rating in a report on Tuesday, February 24th. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, thirteen have given a Hold rating and three have issued a Sell rating to the company’s stock. According to MarketBeat, Pfizer has a consensus rating of “Hold” and a consensus price target of $28.19.

Key Headlines Impacting Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Analyst upgrade/price-target bump: Guggenheim raised its Pfizer price target to $36 and holds a Buy rating, backing upside tied to key pipeline readouts and boosting sentiment among growth/pipeline-focused investors. Guggenheim price target report
• Positive Sentiment: Pipeline upside — prostate cancer and oncology momentum: Several analysts highlight potential high-value outcomes from an ongoing prostate-cancer trial and broader oncology progress, suggesting binary upside that could re-rate the stock if positive. Analyst bullish case on prostate cancer trial
• Neutral Sentiment: Management investor access — Q1 webcast scheduled for May 5: Pfizer invited the public to view a May 5 analyst call tied to its First Quarter 2026 Performance Report; that scheduled update creates a clear near-term catalyst for guidance or pipeline commentary. May 5 webcast invitation
• Neutral Sentiment: Management highlights oncology milestones: CFO Dave Denton discussed recent oncology progress on NYSE Live, reinforcing management’s message that non-COVID franchises and oncology are growth pillars. This supports a constructive narrative but is not immediately revenue-producing. CFO oncology interview
• Negative Sentiment: Lyme vaccine trial—strong efficacy but missed primary endpoint: Pfizer and partner Valneva reported >70% efficacy, yet the trial missed its pre-specified primary endpoint because fewer cases occurred than expected. That creates regulatory and execution uncertainty; Valneva’s shares plunged, underscoring market concern about read-across risk. Pfizer will pursue regulatory filings, but approval risk and timing remain uncertain. Lyme vaccine efficacy and trial miss

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.